CTIS launches Trial SafetyXchange
What happened
CTIS introduced Trial SafetyXchange, a platform designed to help sponsors meet the FDA's upcoming E2B(R3) pharmacovigilance software requirements by supporting standardized safety-reporting workflows. The service aims to smooth the technical compliance path for aggregate and electronic case transmissions as regulators push new data formats. (x.com)
Why it matters
CTIS announced Trial SafetyXchange on April 2, 2026, a cloud-based software service that converts older safety-report files into the FDA’s new structured electronic format and runs automated checks before submission. (businesswire.com) The U.S. regulator set an effective date of April 1, 2026 for sponsors to send individual patient adverse event reports in the new structured electronic format, and set a separate effective date of October 1, 2026 for post‑marketing reports to follow the same data standard. (veeva.com) (federalregister.gov) E2B(R3) is the International Council for Harmonisation (ICH) standard that defines a structured, XML‑based message format for an Individual Case Safety Report — an Individual Case Safety Report being a single‑patient record of an adverse event, the drug taken, patient characteristics, and reporter details — and the R3 revision adds new regional data elements and stricter validation rules for those fields. (database.ich.org) (fda.gov) According to CTIS, Trial SafetyXchange ingests files in the prior E2B(R2) format, automatically converts them to E2B(R3), and runs each converted message through a built‑in validation engine that checks compliance with the ICH E2B(R3) Implementation Guide and the FDA Regional Implementation Guide, all through a 100% web interface that requires no local installs. (ctisinc.com) (businesswire.com) CTIS positions the product for small and mid‑size pharmaceutical companies, biotech firms, and contract research organizations that lack enterprise pharmacovigilance platforms, saying the service offers a faster, lower‑resource route to meet the regulator’s format and validation requirements. (businesswire.com) (ctisinc.com) Public product materials and the live demo site show the platform is available now for commercial use and emphasize rapid onboarding; industry advisories published alongside the regulator’s rollout have warned sponsors and their vendors to confirm mapping logic, case linkage rules, and validator behavior before submitting live files to the FDA. (dev.trialsafetyxchange.com) (veeva.com)
Key numbers
- CTIS introduced Trial SafetyXchange, a platform designed to help sponsors meet the FDA's upcoming E2B(R3) pharmacovigilance software requirements by supporting standardized safety-reporting workflows.
- (x.com) CTIS announced Trial SafetyXchange on April 2, 2026, a cloud-based software service that converts older safety-report files into the FDA’s new structured electronic format and runs automated checks before submission.
What happens next
- The service aims to smooth the technical compliance path for aggregate and electronic case transmissions as regulators push new data formats.
Quick answers
What happened in CTIS launches Trial SafetyXchange?
CTIS introduced Trial SafetyXchange, a platform designed to help sponsors meet the FDA's upcoming E2B(R3) pharmacovigilance software requirements by supporting standardized safety-reporting workflows. The service aims to smooth the technical compliance path for aggregate and electronic case transmissions as regulators push new data formats. (x.com)
Why does CTIS launches Trial SafetyXchange matter?
CTIS announced Trial SafetyXchange on April 2, 2026, a cloud-based software service that converts older safety-report files into the FDA’s new structured electronic format and runs automated checks before submission. (businesswire.com) The U.S. regulator set an effective date of April 1, 2026 for sponsors to send individual patient adverse event reports in the new structured electronic format, and set a separate effective date of October 1, 2026 for post‑marketing reports to follow the same data standard. (veeva.com) (federalregister.gov) E2B(R3) is the International Council for Harmonisation (ICH) standard that defines a structured, XML‑based message format for an Individual Case Safety Report — an Individual Case Safety Report being a single‑patient record of an adverse event, the drug taken, patient characteristics, and reporter details — and the R3 revision adds new regional data elements and stricter validation rules for those fields. (database.ich.org) (fda.gov) According to CTIS, Trial SafetyXchange ingests files in the prior E2B(R2) format, automatically converts them to E2B(R3), and runs each converted message through a built‑in validation engine that checks compliance with the ICH E2B(R3) Implementation Guide and the FDA Regional Implementation Guide, all through a 100% web interface that requires no local installs. (ctisinc.com) (businesswire.com) CTIS positions the product for small and mid‑size pharmaceutical companies, biotech firms, and contract research organizations that lack enterprise pharmacovigilance platforms, saying the service offers a faster, lower‑resource route to meet the regulator’s format and validation requirements. (businesswire.com) (ctisinc.com) Public product materials and the live demo site show the platform is available now for commercial use and emphasize rapid onboarding; industry advisories published alongside the regulator’s rollout have warned sponsors and their vendors to confirm mapping logic, case linkage rules, and validator behavior before submitting live files to the FDA. (dev.trialsafetyxchange.com) (veeva.com)
